Ilan Uchitel, CAPS Medical - Non-thermal Plasma Cancer Treatment | LSI USA '25

Ilan Uchitel  0:03  
Hi my name is Ilan Uchitel, the CEO and co founder of CAPS Medical we have developed technology, minimally inventive technology, that can selectively destroy cancer cells while completely preserving the healthy tissue surrounding that cancer claims close close to 10 million lives annually, making it a leading cause of death. Conventional cancer therapies usually damage the healthy tissue surrounding the tumor, leading to increased mortality and life altering side effects. We're addressing this market need by proposing technology that can completely preserve the healthy tissue surrounding the tumor, and our proprietary technology, plasma sure uses non thermal plasma, which is an ionized gas at near body temperature, to generate a reactive environment around the tumor that includes reactive oxygen, nitrogen, species that can selectively kill cancer cells. They generate stress in cancer cells, leading to cancer cell death by apoptosis. This in line triggers an immune response that propagates into the tissue and destroys similar cancer cells. And all this happening without damaging the healthy tissue surrounding the tumor. So non thermal plasma have been around. They have demonstrated their ability to selectively destroy various types of cancer and are even cleared by the FDA for soft tissue ablation. The problem is that the existing devices today are just using too much energy and just too large to be used inside the body where they needed the most CAPS Medical breakthrough is the device that has the ability, for the first time, to generate the selective, non thermal treatment at a tip of a small diameter, flexible catheter. Now it can be introduced inside the body through working channel of axteen. Minimally invasive tool is a keyhole procedure, and deliver this treatment directly to the tumor inside the body. The amount of energy delivered is monitored in real time throughout the procedure, and the device consists of two main components. We have the capital equipment and the disposable procedure kit, which will be our main revenue driver. Having this small diameter, flexible probe makes us a natural fit to the minimally massive ecosystem, and actually put caps on the focus of interest of all the major play in the markets. In our vision, we're going to address tumors all over the body, endoscopically microscopically thin needles, trocars, assembling it on robotic systems, and always we can use it superficially like everybody else. We're targeting a huge, over $1 billion market. Initially, we're looking at batter cancer, our first initial indication, looking at cn of a clearance towards 2026 and we're already working on clinical plans to expand the technology into esophageal cancer, upper GI lung cancer and additional indications. No resistance to the treatment was observed in any of the treated cell lines in bench test, bench test experiments. And we also demonstrated our ability to deliver the technology inside the body in multiple organs in large animal model. We have already completed a very successful clinical study for first clinical indication, non muscle invasive bladder cancer, NM, IBC, which is the six most common cancer in the world. There are over 1.6 million people suffering from the disease. And the standard of careful which hasn't actually changed for the past several decades. Today, the tumors are being resected using a very traumatic procedure called trbt, which causes perforations, bleeding and other morbid side effects, and then it's supplemented by series of painful into vesicle installation. And yet, the high recurrence rate makes nm IBC, one of the most expensive cancer to treat across patient lifetime, resulting in close to $8 billion annual expenses. So in a successful completed multi center clinical study, we have treated close to 70 tumors endoscopically in place of resection. Out of these tumors, 84% disappeared following a single treatment. We had no device related adverse events, no bleeding, no perforation or anything else. Not only that, there was no local recurrence for any of the treated tumors. Up to one year of follow up, the patients were released the same day. Actually, some of the patients didn't even require anesthesia, and this study clearly demonstrates the advantages of caps, plasma shield technology in preserving the healthy tissue, in this case, bladder tissue, compared to the scarring and the damage to the healthy tissue, which is caused by conventional resection. We're going to revolutionize the standard of care for bladder cancer, initially, for. The low grade disease. We're going to replace resection by utilizing existing reimbursement codes and completely avoiding anesthesia or hospitalization. This procedure will be performed in office as part of regular, regular observation therapy, and we're already working towards our clinical program in addressing the high grade cancer in which our objective will be to postpone or even completely avoid radical cystectomy, the removal bladder. I don't have to explain what it means. We have seven granted and allowed patents and additional over 30 patents pending. On top of that, we have a licensed family of patent from leading academic institutions. Caps team has extensive experience in the healthcare leadership and the proven track record, and the team is supported by world renowned experts in multiple areas of oncology treatment with extensive market access and understanding of the disease today, the company has raised close to $14 million mostly from private European and US investors, a strategic player and non dilutive grants. We're now raising our next round to support the next stages of development, which will include a pivotal study for the initial indication, expansion of the clinical program into additional indication, as well as adjusting our devices to tackle more challenges down the road and to perform the initial preparation to our commercialization. So why CAPS Medical we have a selective, minimally invasive oncology treatment, which is applicable to wide range of tumors. We have very promising clinical data, huge addressable market, a solid go to market strategy. We have a team that performs year after year and meet its timelines and was supported by world renowned experts from leading academic institutions, and we're all devoted to changing the standard of care for treating various types of solid tumors, bringing new hope and lowest indifference in patient's life. Thank you. Applause.